[ $^{68}Ga$ ]is a promising emerging radionuclide for positron emission tomography (PET). It is produced using a $^{68}Ga/^{68}Ga$-generator, and thus, would enable the cyclotronindependent distribution of PET. However, new $^{68}Ga$-labeled radiopharmaceuticals that can replace $^{18}F$-labeled agents like [$^18F$]fluorodeoxyglucose (FDG) are needed. Most of the $^{68}Ga$-labeled derivatives currently used are peptide agents, but the developments of other agents, such as amino acid derivatives, nitroimidazole derivatives, and glycosylated human serum albumin, are being actively pursued in many laboratories. Thus, appearance of new $^{68}Ga$-labeled radiopharmaceuticals with high impact are expected in the near future. Here, we present an overview of $^{68}Ga$-labeled agents in terms of their clinical significances and relevances to the management of certain tumors, and pertinent pre-clinical developments.